Is PHAT or PLRZ more undervalued in 2026?

CirclFi compares Phathom Pharmaceuticals, Inc. (PHAT) and Polyrizon Ltd. (PLRZ) using 13 institutional-grade valuation models. PHAT has a Quality of Company score of 6.1/10 while PLRZ scores 2.3/10.

Which is a better buy — PHAT or PLRZ?

Compare intrinsic values from 13 independent models against current market prices. CirclFi also calculates Value Trap scores. This is not financial advice — conduct your own analysis.

How do PHAT and PLRZ valuations compare?

PHAT at $10.32 and PLRZ at $16.50 are compared across Bayesian DCF, EPV, EROIC Spread, First Chicago, Markov DDM, and 8 additional models.

PHAT vs PLRZ Valuation Comparison 2026 — Intrinsic Value Analysis

PHAT

Biotechnology

Phathom Pharmaceuticals, Inc.

Quality

6.1

out of 10

Value Trap

SAFE

Price

$10.32

Last close

Models

10/13

Active

PLRZ

Biotechnology

Polyrizon Ltd.

Quality

2.3

out of 10

Value Trap

—

Price

$16.50

Last close

Models

9/13

Active

Model-by-Model Comparison

Model	Type	PHAT Fair Value	PHAT Upside	PLRZ Fair Value	PLRZ Upside
Bayesian DCF	Intrinsic	$3.18	-69.1%	$4.37	-73.5%
Earnings Power Value	Intrinsic	$5.33	-55.6%	—	—
EROIC Spread	Intrinsic	$•••.••	••.•%	$•••.••	••.•%
First Chicago	Scenario	$•••.••	••.•%	$•••.••	••.•%
ML-RIV	Intrinsic	$•••.••	••.•%	$•••.••	••.•%
Dynamic NAV	Asset-Based	$•••.••	••.•%	$•••.••	••.•%
PWERM	Option-Based	$•••.••	••.•%	$•••.••	••.•%
Regime Cross-Sectional	Relative	$4.32	-58.1%	$18.67	+13.1%
Sentiment SOTP	Hybrid	$•••.••	••.•%	$•••.••	••.•%
CUCE Ensemble	Ensemble	$•••.••	••.•%	$•••.••	••.•%
FTNN Topology	Relative	$•••.••	••.•%	$•••.••	••.•%

🔒

Unlock Full 13-Model Comparison

Access all valuation models for PHAT vs PLRZ — including EROIC Spread, First Chicago, Markov DDM, PWERM, and 7 more.

Access Full Analysis — From $27/mo →

PHAT vs PLRZ — Which Stock Is More Undervalued?

PHAT scores higher with a 6.1/10 quality rating vs PLRZ's 2.3/10. Both stocks are analyzed daily using SEC EDGAR filings across 13 independent models.

Comparing Phathom Pharmaceuticals, Inc. (PHAT) and Polyrizon Ltd. (PLRZ) across 13 institutional-grade valuation models reveals how each company's intrinsic value stacks up against its market price. CirclFi's engine processes SEC EDGAR 10-K and 10-Q filings, FRED macroeconomic data, and GDELT news sentiment to generate independent fair value estimates daily.

PHAT currently trades at $10.32 with a QOC of 6.1/10, while PLRZ trades at $16.50 with a QOC of 2.3/10.

Both companies are analyzed with models spanning intrinsic (Bayesian DCF, EPV), scenario-based (First Chicago), regime-switching (Markov DDM, RCMH-DCF), machine learning (ML-RIV, FTNN Topology), and ensemble methods (CUCE).